Cannara Biotech Stock Current Valuation
| LOVE Stock | CAD 0.75 0.05 6.25% |
Valuation analysis of Cannara Biotech helps investors to measure Cannara Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to climb to 7.13 in 2024. Enterprise Value Multiple is likely to climb to 7.13 in 2024. Fundamental drivers impacting Cannara Biotech's valuation include:
Price Book 0.8188 | Enterprise Value 113.7 M | Enterprise Value Ebitda 7.4993 | Price Sales 0.9391 | Trailing PE 11.4286 |
Overvalued
Today
Please note that Cannara Biotech's price fluctuation is out of control at this time. Calculation of the real value of Cannara Biotech is based on 3 months time horizon. Increasing Cannara Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cannara stock is determined by what a typical buyer is willing to pay for full or partial control of Cannara Biotech. Since Cannara Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cannara Stock. However, Cannara Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.75 | Real 0.62 | Hype 0.75 | Naive 0.69 |
The intrinsic value of Cannara Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cannara Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cannara Biotech helps investors to forecast how Cannara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cannara Biotech more accurately as focusing exclusively on Cannara Biotech's fundamentals will not take into account other important factors: Cannara Biotech Company Current Valuation Analysis
Cannara Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cannara Biotech Current Valuation | 113.72 M |
Most of Cannara Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cannara Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cannara Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Cannara Biotech is extremely important. It helps to project a fair market value of Cannara Stock properly, considering its historical fundamentals such as Current Valuation. Since Cannara Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cannara Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cannara Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cannara Biotech has a Current Valuation of 113.72 M. This is 99.21% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Canada stocks is 99.32% higher than that of the company.
Cannara Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cannara Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cannara Biotech could also be used in its relative valuation, which is a method of valuing Cannara Biotech by comparing valuation metrics of similar companies.Cannara Biotech is currently under evaluation in current valuation category among its peers.
Cannara Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cannara Biotech from analyzing Cannara Biotech's financial statements. These drivers represent accounts that assess Cannara Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cannara Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 67.8M | 130.1M | 118.4M | 61.2M | 70.4M | 128.1M | |
| Enterprise Value | 72.9M | 142.8M | 154.6M | 103.0M | 118.4M | 143.2M |
Cannara Fundamentals
| Return On Equity | 0.0678 | ||||
| Return On Asset | 0.0378 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 113.72 M | ||||
| Shares Outstanding | 90.02 M | ||||
| Shares Owned By Insiders | 49.42 % | ||||
| Number Of Shares Shorted | 10 | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 0.94 X | ||||
| Revenue | 57.26 M | ||||
| Gross Profit | 17.33 M | ||||
| EBITDA | 14.29 M | ||||
| Net Income | 6.95 M | ||||
| Cash And Equivalents | 5.56 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 5.97 M | ||||
| Debt To Equity | 0.45 % | ||||
| Current Ratio | 2.95 X | ||||
| Book Value Per Share | 0.91 X | ||||
| Cash Flow From Operations | 5.44 M | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | 0.07 X | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 72.02 M | ||||
| Total Asset | 141.52 M | ||||
| Retained Earnings | (19.34 M) | ||||
| Working Capital | 30.51 M | ||||
| Net Asset | 141.52 M |
About Cannara Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cannara Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cannara Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cannara Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.